Form 8-K - Current report:
SEC Accession No. 0001558370-24-014184
Filing Date
2024-11-04
Accepted
2024-11-04 08:30:23
Documents
16
Period of Report
2024-11-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20241104x8k.htm   iXBRL 8-K 47270
2 EX-99.1 nrbo-20241104xex99d1.htm EX-99.1 17329
3 GRAPHIC nrbo-20241104x8k001.jpg GRAPHIC 12152
4 GRAPHIC nrbo-20241104xex99d1001.jpg GRAPHIC 12969
  Complete submission text file 0001558370-24-014184.txt   243174

Data Files

Seq Description Document Type Size
5 EX-101.SCH nrbo-20241104.xsd EX-101.SCH 3148
6 EX-101.LAB nrbo-20241104_lab.xml EX-101.LAB 15928
7 EX-101.PRE nrbo-20241104_pre.xml EX-101.PRE 10071
18 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20241104x8k_htm.xml XML 4871
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 241420947
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)